1. Home
  2. UVV vs LBRX Comparison

UVV vs LBRX Comparison

Compare UVV & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Corporation

UVV

Universal Corporation

SELL

Current Price

$37.73

Market Cap

1.1B

Sector

Industrials

ML Signal

SELL

Logo LB Pharmaceuticals Inc

LBRX

LB Pharmaceuticals Inc

SELL

Current Price

$42.87

Market Cap

1.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
UVV
LBRX
Founded
1886
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
1994
2025

Fundamental Metrics

Financial Performance
Metric
UVV
LBRX
Price
$37.73
$42.87
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
★ $58.00
AVG Volume (30 Days)
★ 379.7K
325.5K
Earning Date
11-04-2026
11-05-2026
Dividend Yield
★ 8.83%
N/A
EPS Growth
N/A
★ 98.22
EPS
★ 0.30
N/A
Revenue
★ $2,885,078,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.17
N/A
P/E Ratio
$125.27
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$37.38
$15.19
52 Week High
$59.38
$50.16

Technical Indicators

Market Signals
Indicator
UVV
LBRX
Relative Strength Index (RSI) 35.46 56.82
Support Level N/A $37.99
Resistance Level $54.25 $49.74
Average True Range (ATR) 1.29 2.53
MACD -0.10 0.36
Stochastic Oscillator 6.14 63.95

Price Performance

Historical Comparison
UVV
LBRX

About UVV Universal Corporation

Universal Corp is an international leaf tobacco supplier. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Tobacco Operations segment involves procuring and processing flue-cured, burley, dark air-cured, and oriental leaf tobacco for manufacturers of consumer tobacco products and performing related services. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, the Philippines, Germany, and Other Countries, with the majority of revenue from the USA.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.

Share on Social Networks: